{"id":70747,"date":"2026-05-12T10:39:40","date_gmt":"2026-05-12T10:39:40","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=70747"},"modified":"2026-10-15T10:33:58","modified_gmt":"2026-10-15T10:33:58","slug":"cagrilintide","status":"publish","type":"product","link":"https:\/\/medsbase.com\/pt-pt\/product\/cagrilintide\/","title":{"rendered":"Cagrilintide"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Resposta R\u00e1pida \u2014 O que \u00e9 a Cagrilintida?<\/h3>\n<p style=\"margin: 0;\"><strong>Cagrilintide<\/strong> (developmental code AM833) is a 37-amino-acid long-acting synthetic amylin analog developed by Novo Nordisk. It is the lead amylin-class peptide in current metabolic support and the partner compound in the CagriSema combination (cagrilintide + <a href=\"https:\/\/medsbase.com\/pt-pt\/semaglutide\/\">semaglutide<\/a>), now in late-stage Phase 3 trials for obesity and type 2 diabetes. Plasma half-life ~159 hours enables once-weekly dosing. Supplied in 5\u00a0mg and 10\u00a0mg lyophilized vials.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>O que obt\u00e9m com a MedsBase:<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/pt-pt\/reviews\/\">de clientes<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Cada encomenda est\u00e1 coberta pela nossa <a href=\"https:\/\/medsbase.com\/pt-pt\/medsbase-re-shipment-assurance-policy\/\"><strong>Pol\u00edtica de Garantia de Reenvio<\/strong><\/a> \u2014 se a sua encomenda n\u00e3o chegar no prazo de 20 dias \u00fateis, reenviamo-la.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Especifica\u00e7\u00e3o<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Detalhe<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>N\u00famero CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">1415456-99-3 (cagrilintide; frequentemente citado)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Tipo<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">~4,981 Da (com acila\u00e7\u00e3o de \u00e1cido di\u00e1cido C20 e ponte dissulfeto intramolecular)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Peso Molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">~4,981 Da (com acila\u00e7\u00e3o de \u00e1cido di\u00e1cido gordo C20 e ponte dissulfureto intramolecular)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Estrutura<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">37 amino\u00e1cidos baseados na estrutura da amilina humana com substitui\u00e7\u00f5es que reduzem a agrega\u00e7\u00e3o formadora de amiloide, uma ponte dissulfeto intramolecular Cys2\u2013Cys7 necess\u00e1ria para a liga\u00e7\u00e3o ao recetor, e uma cadeia acil de \u00e1cido di\u00e1cido C20 ligada atrav\u00e9s de um espa\u00e7ador \u03b3-Glu-OEG-OEG que promove uma forte liga\u00e7\u00e3o revers\u00edvel \u00e0 albumina s\u00e9rica para a meia-vida semanal. C-terminal amidado.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forma<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">P\u00f3 liofilizado (branco a branco sujo)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Pureza<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (HPLC verificado, COA dispon\u00edvel mediante pedido)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Armazenamento<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Liofilizado: 2\u20138 \u00b0C (frigor\u00edfico) para stock de trabalho; \u221220 \u00b0C para armazenamento a longo prazo de frascos n\u00e3o abertos. Reconstitu\u00eddo: 2\u20138 \u00b0C, utilizar no prazo de ~30 dias. Proteger da luz. N\u00e3o congelar-descongelar a solu\u00e7\u00e3o reconstitu\u00edda.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilidade<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u00c1gua bacteriost\u00e1tica (recomendada) ou \u00e1gua est\u00e9ril para per\u00edodos de utiliza\u00e7\u00e3o mais curtos. Os pept\u00eddeos acilados podem dissolver-se mais lentamente do que pept\u00eddeos n\u00e3o modificados de menor dimens\u00e3o \u2014 permita um tempo de equil\u00edbrio adicional.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>\u00e9 um an\u00e1logo sint\u00e9tico de longa a\u00e7\u00e3o da amilina \u2014 um hormona pept\u00eddica pancre\u00e1tica de 37 amino\u00e1cidos co-secretada com a insulina pelas c\u00e9lulas beta e um dos principais reguladores end\u00f3genos da excurs\u00e3o glic\u00e9mica p\u00f3s-prandial, sinaliza\u00e7\u00e3o de saciedade e esvaziamento g\u00e1strico. A amilina humana end\u00f3gena tem uma meia-vida plasm\u00e1tica curta (~13 minutos), farmacocin\u00e9tica pobre e uma forte tend\u00eancia para formar agregados amiloides (o mesmo amiloide das ilhotas que se acumula no tecido pancre\u00e1tico de diab\u00e9ticos tipo 2). A Cagrilintida foi desenvolvida pela Novo Nordisk (c\u00f3digo de desenvolvimento AM833) para superar cada uma destas limita\u00e7\u00f5es: substitui\u00e7\u00f5es para reduzir a agrega\u00e7\u00e3o, uma ponte dissulfeto intramolecular preservada para a liga\u00e7\u00e3o ao recetor, e uma cadeia acilada de \u00e1cido di\u00e1cido C20 ligada atrav\u00e9s de um espa\u00e7ador \u03b3-Glu-OEG-OEG que promove uma forte liga\u00e7\u00e3o revers\u00edvel \u00e0 albumina s\u00e9rica. O efeito combinado \u00e9 uma meia-vida plasm\u00e1tica de aproximadamente 159 horas (~6,5 dias), permitindo uma dosagem semanal subcut\u00e2nea em investiga\u00e7\u00e3o.<\/h2>\n<p><strong>Cagrilintide<\/strong> is a long-acting synthetic analog of amylin \u2014 a 37-amino-acid pancreatic peptide hormone co-secreted with insulin from beta cells and one of the principal endogenous regulators of postprandial glucose excursion, satiety signalling, and gastric emptying. Endogenous human amylin has a short plasma half-life (~13 minutes), poor pharmacokinetics, and a strong tendency to form amyloid aggregates (the same islet amyloid that accumulates in type 2 diabetic pancreas tissue). Cagrilintide was engineered by Novo Nordisk (developmental code AM833) to overcome each of these limitations: substitutions to reduce aggregation, an intramolecular disulfide bridge preserved for receptor binding, and a C20 fatty-diacid acyl chain attached via a \u03b3-Glu-OEG-OEG spacer that drives strong reversible binding to circulating serum albumin. The combined effect is a plasma half-life of approximately 159 hours (~6.5 days), enabling once-weekly subcutaneous dosing. Cagrilintide has a mature molecular weight of approximately 4,981\u00a0Da including the acyl chain and disulfide bridge. The intramolecular Cys2\u2013Cys7 disulfide is essential for receptor binding \u2014 reduction of this bond converts the peptide into an inactive linear form. The fatty-acid tether is one carbon longer than semaglutide&#8217;s C18 acyl chain, producing the long half-life through the same albumin-binding mechanism. Cagrilintide is the most advanced compound in the renewed wave of amylin-pathway pharmacology, with the lead clinical programme being the <strong>\u2014 cagrilintida 2,4 mg +<\/strong> 2,4 mg semanal \u2014 que completou os ensaios de Fase 3 REDEFINE-1 (obesidade) e REDEFINE-2 (DM2) com redu\u00e7\u00f5es de peso corporal de aproximadamente 20\u201323% ao longo de 68 semanas. A Cagrilintida \u00e9 <a href=\"https:\/\/medsbase.com\/pt-pt\/semaglutide\/\">semaglutide<\/a> 2,4 mg semanais \u2014 que completaram os ensaios de Fase 3 REDEFINE-1 (obesidade) e REDEFINE-2 (DM2) com redu\u00e7\u00f5es de peso corporal de aproximadamente 20\u201323% ao longo de 68 semanas. O Cagrilintide \u00e9 <strong>aprovado<\/strong> by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use as a stand-alone agent or in combination. <\/p>\n<h2>Mecanismo de A\u00e7\u00e3o \u2014 Agonismo do Receptor de Amilina em Locais Centrais e Perif\u00e9ricos<\/h2>\n<p>O que torna a cagrilintida farmacologicamente distinta dos agonistas do GLP-1 \u00e9 que atua num <strong>sistema receptor completamente diferente \u2014 a fam\u00edlia de receptores de amilina\/calcitonina \u2014 atrav\u00e9s de tr\u00eas mecanismos principais<\/strong> documented in published studies:<\/p>\n<ul>\n<li><strong>Agonismo do receptor de amilina (AMY1, AMY2, AMY3) \u2014 circuitos de saciedade no tronco cerebral<\/strong> \u2014 Os receptores de amilina s\u00e3o heterod\u00edmeros do receptor de calcitonina (CTR) com prote\u00ednas modificadoras da atividade do receptor RAMP1, RAMP2 e RAMP3, gerando os subtipos de receptor AMY1, AMY2 e AMY3. O principal local de a\u00e7\u00e3o para a sinaliza\u00e7\u00e3o de saciedade \u00e9 a \u00e1rea postrema no tronco cerebral \u2014 uma das poucas regi\u00f5es do SNC que n\u00e3o possui uma barreira hematoencef\u00e1lica, permitindo o acesso direto da amilina circulante e an\u00e1logos acilados como a cagrilintida. A ativa\u00e7\u00e3o dos receptores AMY no tronco cerebral desencadeia proje\u00e7\u00f5es vagais e noradren\u00e9rgicas para o hipot\u00e1lamo, suprimindo a ingest\u00e3o de alimentos numa escala temporal por refei\u00e7\u00e3o.<\/li>\n<li><strong>Supress\u00e3o do glucagon e atraso no esvaziamento g\u00e1strico<\/strong> \u2014 Al\u00e9m da saciedade central, a cagrilintida reproduz as a\u00e7\u00f5es metab\u00f3licas perif\u00e9ricas da amilina: supress\u00e3o dependente de glucose da secre\u00e7\u00e3o de glucagon pelas c\u00e9lulas alfa pancre\u00e1ticas, redu\u00e7\u00e3o da produ\u00e7\u00e3o hep\u00e1tica de glucose p\u00f3s-prandial e atraso pronunciado no esvaziamento g\u00e1strico. O atraso no esvaziamento g\u00e1strico refor\u00e7a a saciedade ao prolongar o sinal de saciedade p\u00f3s-refei\u00e7\u00e3o e reduz a magnitude da excurs\u00e3o de glucose p\u00f3s-prandial. Desenvolve-se taquifilaxia (dessensibiliza\u00e7\u00e3o parcial) do atraso no esvaziamento g\u00e1strico ao longo de semanas de ocupa\u00e7\u00e3o cont\u00ednua do receptor, paralelamente ao padr\u00e3o do eixo GLP-1.<\/li>\n<li><strong>Mecanismo complementar ao GLP-1 \u2014 a racionalidade do CagriSema<\/strong> \u2014 A justifica\u00e7\u00e3o cl\u00ednica para combinar cagrilintida com <a href=\"https:\/\/medsbase.com\/pt-pt\/semaglutide\/\">semaglutide<\/a> baseia-se em mecanismos n\u00e3o sobrepostos. Os agonistas GLP-1 atuam predominantemente nos neur\u00f3nios POMC do n\u00facleo arqueado hipotal\u00e2mico (regula\u00e7\u00e3o da ingest\u00e3o alimentar atrav\u00e9s do sistema central de apetite) e nas c\u00e9lulas beta pancre\u00e1ticas (secre\u00e7\u00e3o de insulina dependente da glucose). Os agonistas da amilina atuam predominantemente nos recetores AMY da \u00e1rea postrema do tronco cerebral (refor\u00e7o da saciedade por refei\u00e7\u00e3o) e nas c\u00e9lulas alfa pancre\u00e1ticas (supress\u00e3o do glucagon). Os dois mecanismos s\u00e3o mecanicamente aditivos em vez de sobrepostos, raz\u00e3o pela qual o CagriSema produz efeitos no peso corporal nos ensaios de Fase 3 que se aproximam da magnitude do triplo agonista <a href=\"https:\/\/medsbase.com\/pt-pt\/retatrutide\/\">retatrutide<\/a> sem passar pelo recetor GIP ou do glucagon.<\/li>\n<\/ul>\n<p>The C20 fatty-diacid acylation at lysine (analogous to semaglutide&#8217;s C18 modification) drives reversible serum-albumin binding that produces the ~159-hour plasma half-life. The intramolecular Cys2\u2013Cys7 disulfide bridge maintains the bioactive conformation required for AMY-receptor binding \u2014 users must avoid vigorous shaking or freeze-thaw cycles that could disrupt the disulfide. Subcutaneous administration is the standard administration route and the only route used in clinical development. <\/p>\n<h2>Published Evidence<\/h2>\n<p>Cagrilintide is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Obesidade e regula\u00e7\u00e3o do peso corporal<\/strong> \u2014 preclinical DIO (diet-induced obesity) rodent models, body-composition (DEXA\/MRI), food-intake assays, energy-expenditure characterisation; canonical peptide for the renewed amylin-pathway pharmacology programme<\/li>\n<li><strong>Combined cagrilintide + GLP-1 (CagriSema) studies<\/strong> \u2014 estudos comparativos e de combina\u00e7\u00e3o com <a href=\"https:\/\/medsbase.com\/pt-pt\/semaglutide\/\">semaglutide<\/a> em modelos de obesidade e DM2; disseca\u00e7\u00e3o mecanicista dos efeitos complementares vs aditivos vs sin\u00e9rgicos no peso corporal (Enebo et al., Lancet 2021; resultados da Fase 3 do CagriSema)<\/li>\n<li><strong>Type 2 diabetes preclinical studies<\/strong> \u2014 controlo glic\u00e9mico, supress\u00e3o do glucagon, excurs\u00e3o glic\u00e9mica p\u00f3s-prandial em modelos de roedores com dieta rica em gordura<\/li>\n<li><strong>Farmacologia do recetor da amilina<\/strong> \u2014 seletividade do subtipo de recetor AMY1 \/ AMY2 \/ AMY3, sinaliza\u00e7\u00e3o dependente de RAMP, pot\u00eancia comparativa do agonista nos recetores da calcitonina vs amilina<\/li>\n<li><strong>Brainstem satiety-circuit studies<\/strong> \u2014 ativa\u00e7\u00e3o espec\u00edfica do recetor da \u00e1rea postrema, mapeamento das proje\u00e7\u00f5es vagais e noradren\u00e9rgicas, distin\u00e7\u00e3o dos mecanismos GLP-1 do n\u00facleo arqueado<\/li>\n<li><strong>Gastric emptying and postprandial physiology studies<\/strong> \u2014 tempo de esvaziamento g\u00e1strico, din\u00e2mica da glucose p\u00f3s-prandial, integra\u00e7\u00e3o do eixo intestino-hormona<\/li>\n<li><strong>Comparative incretin\/amylin peptide studies<\/strong> \u2014 compara\u00e7\u00e3o com agonista \u00fanico de GLP-1 (<a href=\"https:\/\/medsbase.com\/pt-pt\/semaglutide\/\">Semaglutide<\/a>), agonista duplo de GIP\/GLP-1 (<a href=\"https:\/\/medsbase.com\/pt-pt\/tirzepatide\/\">Tirzepatide<\/a>), e agonista triplo de GLP-1\/GIP\/glucagon (<a href=\"https:\/\/medsbase.com\/pt-pt\/retatrutide\/\">Retatrutide<\/a>) quanto ao efeito no peso corporal, controlo glic\u00e9mico e perfil de efeitos secund\u00e1rios.<\/li>\n<\/ul>\n<p>Para um contexto mais amplo sobre o posicionamento da cagrilintida no panorama dos pept\u00eddeos metab\u00f3licos, consulte <a href=\"https:\/\/medsbase.com\/pt-pt\/semaglutide\/\">Semaglutide<\/a> como parceiro da combina\u00e7\u00e3o CagriSema, <a href=\"https:\/\/medsbase.com\/pt-pt\/tirzepatide\/\">Tirzepatide<\/a> como comparador de recetor duplo, e <a href=\"https:\/\/medsbase.com\/pt-pt\/retatrutide\/\">Retatrutide<\/a> como comparador de recetor triplo. Explore a completa <a href=\"https:\/\/medsbase.com\/pt-pt\/peptides\/\">cat\u00e1logo de p\u00e9ptidos<\/a> para encontrar compostos relacionados. <\/p>\n<h2>For\u00e7as e Concentra\u00e7\u00f5es Dispon\u00edveis<\/h2>\n<p>MedsBase stocks Cagrilintide in two lyophilized vial sizes calibrated to typical protocol lengths. Each strength is available in 10-vial, 20-vial, or 30-vial pack formats with full reconstitution guidance:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">For\u00e7a do frasco<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Caso de uso t\u00edpico<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tamanhos das embalagens<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>5\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength \u2014 pilot dosing, single-cohort protocols, short-cycle titration studies<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Protocolos de ciclo prolongado, estudos de m\u00faltiplas coortes, menor custo por mg<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Both strengths are the same chemical form (lyophilized powder, 99%+ HPLC purity). Phase 3 clinical doses are 2.4\u00a0mg weekly (the CagriSema arm), so pharmaceutical-grade vials at 5\u00a0mg or 10\u00a0mg represent multi-week supplies of clinical-equivalent dosing for in-vivo work. Cagrilintide is a comparatively scarce peptide because of the structural complexity (disulfide bridge + acyl tether) and ongoing clinical development controls, which is reflected in the per-mg price relative to small synthetic peptides. <\/p>\n<h2>Como Compara \u2014 Cagrilintida vs Semaglutida<\/h2>\n<p>Cagrilintide e <a href=\"https:\/\/medsbase.com\/pt-pt\/semaglutide\/\">Semaglutide<\/a> s\u00e3o as duas metades da combina\u00e7\u00e3o CagriSema \u2014 o principal composto cl\u00ednico da Fase 3 na farmacologia atual da obesidade. Atuam em sistemas de recetores completamente diferentes (amilina\/calcitonina vs GLP-1) e produzem efeitos mecanicamente complementares: refor\u00e7o da saciedade pelo eixo da amilina e supress\u00e3o do glucagon por um lado, regula\u00e7\u00e3o do apetite pelo eixo GLP-1 e secre\u00e7\u00e3o de insulina dependente da glucose por outro. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Crit\u00e9rio<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Cagrilintide<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Semaglutide<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Fam\u00edlia de recetores<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Fam\u00edlia de recetores de amilina\/calcitonina (AMY1\/2\/3)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Recetor de GLP-1 (GLP-1R)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Comprimento<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">37 amino\u00e1cidos<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">31 amino\u00e1cidos<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Alvo prim\u00e1rio no SNC<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u00c1rea postrema do tronco cerebral<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">N\u00facleo arqueado hipotal\u00e2mico (neur\u00f3nios POMC)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Efeitos perif\u00e9ricos<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Supress\u00e3o de glucagon, esvaziamento g\u00e1strico retardado<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Secre\u00e7\u00e3o de insulina, supress\u00e3o de glucagon, esvaziamento g\u00e1strico<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Liga\u00e7\u00e3o de \u00e1cido gordo<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">C20 di\u00e1cido + \u03b3Glu-OEG-OEG<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">C18 di\u00e1cido + \u03b3Glu-AEEA-AEEA<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Meia-vida<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~159 horas (~6,5 dias)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~165 horas (~7 dias)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Refer\u00eancia da marca<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Investigacional (AM833; combina\u00e7\u00e3o CagriSema)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Ozempic \/ Wegovy \/ Rybelsus<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Efeito no peso corporal (monoterapia)<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~10% (Fase 2 de monoterapia)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~15% (ensaios STEP)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Combinado (CagriSema)<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\" colspan=\"2\">~20\u201323% de redu\u00e7\u00e3o de peso corporal com 2,4 mg + 2,4 mg semanais (REDEFINE-1 Fase 3)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For studies interested in the amylin axis specifically, cagrilintide is the canonical long-acting peptide. For studies interested in maximal body-weight effect via combination pharmacology, the CagriSema model (cagrilintide + <a href=\"https:\/\/medsbase.com\/pt-pt\/semaglutide\/\">semaglutide<\/a>) \u00e9 a refer\u00eancia principal. Para compara\u00e7\u00e3o com a abordagem de empilhamento de recetores utilizada por agonistas m\u00faltiplos de mol\u00e9cula \u00fanica, consulte <a href=\"https:\/\/medsbase.com\/pt-pt\/tirzepatide\/\">Tirzepatide<\/a> (duplo GLP-1\/GIP) e <a href=\"https:\/\/medsbase.com\/pt-pt\/retatrutide\/\">Retatrutide<\/a> (triplo GLP-1\/GIP\/glucagon). <\/p>\n<h2>Armazenamento e Reconstitui\u00e7\u00e3o<\/h2>\n<p><strong>Antes da reconstitui\u00e7\u00e3o:<\/strong> Armazene os frascos liofilizados refrigerados a 2\u20138 \u00b0C na embalagem original para stock de trabalho a curto prazo. Para armazenamento a longo prazo sem abertura, congele a \u221220 \u00b0C. O cagrilintida liofilizado \u00e9 est\u00e1vel sob refrigera\u00e7\u00e3o por at\u00e9 24 meses e a \u221220 \u00b0C por at\u00e9 36 meses. Evite ciclos de congela\u00e7\u00e3o-descongela\u00e7\u00e3o no p\u00f3 liofilizado. Como outros p\u00e9ptidos com pontes dissulfureto, a liga\u00e7\u00e3o do cagrilintida ao recetor depende da liga\u00e7\u00e3o intacta Cys2\u2013Cys7 \u2014 manipula\u00e7\u00f5es que perturbem a ponte dissulfureto degradar\u00e3o a atividade. <strong>Procedimento de reconstitui\u00e7\u00e3o:<\/strong> inject bacteriostatic water down the side wall of the vial (not directly onto the lyophilized cake). For a 5\u00a0mg vial, 2.0\u00a0mL of bacteriostatic water yields a 2.5\u00a0mg\/mL working concentration \u2014 0.04\u00a0mL delivers 100\u00a0mcg; 0.1\u00a0mL delivers 250\u00a0mcg; ~1.0\u00a0mL delivers a clinical-equivalent 2.4\u00a0mg dose. Swirl gently \u2014 do <strong>n\u00e3o<\/strong> agite vigorosamente \u2014 e aguarde 5\u201310 minutos para dissolu\u00e7\u00e3o completa. P\u00e9ptidos acilados dissolvem-se mais lentamente do que p\u00e9ptidos n\u00e3o modificados mais pequenos; n\u00e3o apresse este passo. Uma solu\u00e7\u00e3o corretamente reconstitu\u00edda deve ser l\u00edmpida e incolor, sem part\u00edculas vis\u00edveis. <strong>Ap\u00f3s reconstitui\u00e7\u00e3o:<\/strong> Armazene refrigerado a 2\u20138 \u00b0C e utilize no prazo de 30 dias para estabilidade \u00f3tima. N\u00e3o congele a solu\u00e7\u00e3o reconstitu\u00edda \u2014 ciclos de congela\u00e7\u00e3o-descongela\u00e7\u00e3o degradam a integridade do p\u00e9ptido e podem perturbar a liga\u00e7\u00e3o dissulfureto Cys2\u2013Cys7. Descarte qualquer frasco que apresente turva\u00e7\u00e3o, precipitado ou descolora\u00e7\u00e3o. <\/p>\n<h2 id=\"faqs\">Perguntas Frequentes<\/h2>\n<h3>What is Cagrilintide used for in studies?<\/h3>\n<p>Cagrilintide is used in studies investigating the amylin\/calcitonin receptor axis, brainstem area-postrema satiety circuits, postprandial glucose physiology, gastric emptying, obesity and body-weight regulation, type 2 diabetes preclinical models, and especially combination pharmacology with GLP-1 agonists (the CagriSema study model with <a href=\"https:\/\/medsbase.com\/pt-pt\/semaglutide\/\">semaglutide<\/a>). It is the most-cited long-acting amylin analog in current metabolic-peptide studies. The pharmaceutical-grade cagrilintide sold here is <strong>n\u00e3o<\/strong> FDA-approved and is supplied strictly for clinical studies use only. <\/p>\n<h3>O que \u00e9 o CagriSema?<\/h3>\n<p>CagriSema \u00e9 o nome de desenvolvimento para a combina\u00e7\u00e3o em dose fixa de <strong>cagrilintida + semaglutida<\/strong> a 2,4 mg + 2,4 mg semanal. \u00c9 o principal programa de obesidade em Fase 3 da Novo Nordisk \u2014 os ensaios REDEFINE-1 e REDEFINE-2 reportaram redu\u00e7\u00f5es de peso corporal de aproximadamente 20\u201323% ao longo de 68 semanas, colocando o CagriSema na mesma faixa de tamanho de efeito que o <a href=\"https:\/\/medsbase.com\/pt-pt\/retatrutide\/\">retatrutide<\/a> enquanto segue uma rota mecanicista completamente diferente (combina\u00e7\u00e3o de dois agonistas de recetor \u00fanico em vez de uma \u00fanica mol\u00e9cula multi-agonista). O Cagrilintida \u00e9 a componente amilina desta combina\u00e7\u00e3o. <\/p>\n<h3>Como \u00e9 que o Cagrilintida difere da Semaglutida?<\/h3>\n<p>A diferen\u00e7a fundamental \u00e9 o sistema de recetores. O Cagrilintida atua na fam\u00edlia de recetores da amilina\/calcitonina (AMY1, AMY2, AMY3) com efeitos centrais prim\u00e1rios na \u00e1rea postrema do tronco cerebral. A Semaglutida atua no recetor do GLP-1 com efeitos centrais prim\u00e1rios no n\u00facleo arqueado do hipot\u00e1lamo. Os dois s\u00e3o farmacologicamente complementares, n\u00e3o concorrentes \u2014 a sua combina\u00e7\u00e3o no CagriSema produz efeitos aditivos no peso corporal superiores a qualquer um isoladamente. Ambos s\u00e3o p\u00e9ptidos de a\u00e7\u00e3o prolongada com acila\u00e7\u00e3o de \u00e1cido gordo C20 \/ C18 que permite dosagem semanal \u00fanica. <\/p>\n<h3>Como \u00e9 que o Cagrilintida difere do Tirzepatida?<\/h3>\n<p>Tirzepatide is a single molecule that activates two receptors (dual GLP-1\/GIP agonist). Cagrilintide activates only the amylin\/calcitonin receptor family. For studies interested in body-weight magnitude beyond single-receptor GLP-1, tirzepatide takes the \u201creceptor-stacking in one molecule\u201d approach while CagriSema (cagrilintide + semaglutide) takes the \u201cseparate molecules in combination\u201d approach. The two strategies have produced comparable body-weight effect sizes in their respective Phase 3 trials. <\/p>\n<h3>What is the typical Cagrilintide dose?<\/h3>\n<p>Published preclinical and clinical studies protocols use weekly subcutaneous dosing with a titration schedule starting at 0.16\u00a0mg and increasing through 0.3, 0.6, 1.2, and finally 2.4\u00a0mg maintenance weekly \u2014 the same dose used in the CagriSema combination. A 5\u00a0mg vial reconstituted with 2.0\u00a0mL bacteriostatic water yields 2.5\u00a0mg\/mL \u2014 approximately 1.0\u00a0mL equals a 2.4\u00a0mg clinical-equivalent dose. <\/p>\n<h3>O Cagrilintide \u00e9 aprovado pela FDA?<\/h3>\n<p>No. Cagrilintide is not approved by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use as either a stand-alone agent or in the CagriSema combination. CagriSema Phase 3 trials (REDEFINE-1 obesity, REDEFINE-2 T2DM) have reported positive results but regulatory submission and review remain ongoing as of current literature. <\/p>\n<h3>Como deve ser armazenado o Cagrilintide?<\/h3>\n<p>Frascos liofilizados: refrigerados a 2\u20138 \u00b0C para estoque de trabalho de curto prazo, ou \u221220 \u00b0C para armazenamento de longo prazo de frascos n\u00e3o abertos. Solu\u00e7\u00e3o reconstitu\u00edda: refrigerada a 2\u20138 \u00b0C, utilizar dentro de 30 dias. N\u00e3o congele a solu\u00e7\u00e3o reconstitu\u00edda \u2014 os ciclos de congela\u00e7\u00e3o e descongela\u00e7\u00e3o degradam o p\u00e9ptido e podem perturbar a ponte dissulfeto essencial Cys2\u2013Cys7. Proteger da luz direta em todos os momentos. <\/p>\n<h3>Como reconstituir o Cagrilintide?<\/h3>\n<p>Siga o procedimento de reconstitui\u00e7\u00e3o acima. Adicione \u00e1gua bacteriost\u00e1tica pela parede lateral do frasco (n\u00e3o diretamente sobre o p\u00f3 liofilizado), agite suavemente e deixe repousar durante 5\u201310 minutos para dissolu\u00e7\u00e3o completa (os p\u00e9ptidos acilados dissolvem-se mais lentamente do que os p\u00e9ptidos menores n\u00e3o modificados). N\u00e3o <strong>n\u00e3o<\/strong> agite o frasco. Uma solu\u00e7\u00e3o corretamente reconstitu\u00edda \u00e9 clara e incolor, sem part\u00edculas vis\u00edveis. Para um frasco de 5 mg + 2,0 mL de diluente, a concentra\u00e7\u00e3o de trabalho \u00e9 de 2,5 mg\/mL. <\/p>\n<h3>Que dosagens est\u00e3o dispon\u00edveis na MedsBase?<\/h3>\n<p>MedsBase carries Cagrilintide in 5\u00a0mg and 10\u00a0mg lyophilized vials. Each strength is available in 10-vial, 20-vial, or 30-vial pack sizes. All vials are supplied at 99%+ HPLC purity with a certificate of analysis available on request. <\/p>\n<h3>Por que o Cagrilintide \u00e9 mais caro do que outros pept\u00eddeos?<\/h3>\n<p>Cagrilintide is structurally complex (37 amino acids with an intramolecular disulfide bridge and a fatty-diacid acyl chain) and is a relatively recent compound still under active clinical development by Novo Nordisk. Both factors contribute to higher synthesis cost and constrained supply relative to mature small synthetic peptides like BPC-157 or TB-500. The per-mg price reflects these supply-and-complexity factors rather than any difference in studies utility. <\/p>\n<h3>Can Cagrilintide be paired with Semaglutide in studies?<\/h3>\n<p>Yes \u2014 this is the canonical CagriSema protocol and the lead Phase 3 clinical combination. Cagrilintide and semaglutide act on different receptor families (amylin\/calcitonin vs GLP-1) with non-overlapping central and peripheral mechanisms, producing additive body-weight effects substantially greater than either alone. The clinical fixed-dose ratio is 2.4\u00a0mg cagrilintide + 2.4\u00a0mg semaglutide weekly. <\/p>\n<h3>Does Cagrilintide cause side reported effects?<\/h3>\n<p>Like other satiety-axis peptides, the most consistent finding is gastrointestinal \u2014 nausea, transient appetite suppression, and delayed gastric emptying are dose-dependent and tend to attenuate over 4\u20138 weeks of continuous dosing as receptor tachyphylaxis develops. Because cagrilintide is the amylin analog and not a GLP-1, the gastrointestinal profile differs from semaglutide in pattern, but the magnitude is comparable in published clinical studies. Long-term safety data continues to accumulate from Phase 3 trials. <\/p>\n<h3>Qual \u00e9 a meia-vida do Cagrilintide?<\/h3>\n<p>Cagrilintide has a plasma half-life of approximately 159 hours (~6.5 days) following subcutaneous administration. The extended half-life is achieved by reversible binding to circulating serum albumin via the C20 fatty-diacid tether at lysine, which protects the peptide from renal clearance. The half-life is comparable to semaglutide&#8217;s ~165 hours, allowing both compounds to be co-dosed weekly in CagriSema studies without divergent pharmacokinetics. <\/p>\n<h3>How long does Cagrilintide take to show effects in preclinical studies?<\/h3>\n<p>Os efeitos farmacodin\u00e2micos agudos no esvaziamento g\u00e1strico e na saciedade por refei\u00e7\u00e3o s\u00e3o detet\u00e1veis poucas horas ap\u00f3s a primeira dose. Os efeitos no peso corporal em modelos de roedores DIO tornam-se tipicamente estatisticamente significativos ap\u00f3s 1\u20132 semanas de dosagem semanal e continuam a acumular-se ao longo de 8\u201312 semanas. O efeito m\u00e1ximo na composi\u00e7\u00e3o corporal desenvolve-se ao longo de 16\u201324 semanas de dosagem cont\u00ednua, espelhando a trajet\u00f3ria da Fase 3 humana no REDEFINE-1. <\/p>\n<h3>Posso encomendar Cagrilintide para envio internacional?<\/h3>\n<p>Sim. A MedsBase envia Cagrilintide para todo o mundo a partir da nossa rede dedicada de envio de pept\u00eddeos. As encomendas exclusivas de pept\u00eddeos qualificam-se para o nosso servi\u00e7o de envio de pept\u00eddeos independente. Todas as encomendas s\u00e3o enviadas em embalagens com controlo de temperatura com rastreio completo e est\u00e3o cobertas pela nossa <a href=\"https:\/\/medsbase.com\/pt-pt\/medsbase-re-shipment-assurance-policy\/\">Pol\u00edtica de Garantia de Reenvio<\/a>. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for Metabolic, Body-Composition, and Satiety-Axis Studies<\/h2>\n<ul>\n<li><a href=\"\/pt-pt\/semaglutide\/\"><strong>Semaglutide<\/strong><\/a> \u2014 Single GLP-1 agonist \u2014 CagriSema combination partner; canonical glycaemic and CV-studies comparator<\/li>\n<li><a href=\"\/pt-pt\/tirzepatide\/\"><strong>Tirzepatide<\/strong><\/a> \u2014 Agonista duplo GLP-1\/GIP \u2014 comparador de empilhamento de recetores numa mol\u00e9cula<\/li>\n<li><a href=\"\/pt-pt\/retatrutide\/\"><strong>Retatrutide<\/strong><\/a> \u2014 Triple GLP-1\/GIP\/glucagon agonist \u2014 multi-axis metabolic support<\/li>\n<li><a href=\"\/pt-pt\/mots-c\/\"><strong>MOTS-c<\/strong><\/a> \u2014 Mitochondrially-encoded peptide \u2014 AMPK and insulin sensitivity<\/li>\n<li><a href=\"\/pt-pt\/tesamorelin\/\"><strong>Tesamorelin<\/strong><\/a> \u2014 GHRH analog \u2014 visceral adiposity<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>Leitura Adicional<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 Explore o panorama das combina\u00e7\u00f5es de pept\u00eddeos metab\u00f3licos<\/strong><\/p>\n<p style=\"margin: 0;\">Explore a gama completa <a href=\"https:\/\/medsbase.com\/pt-pt\/peptides\/\"><strong>cat\u00e1logo de p\u00e9ptidos<\/strong><\/a>, com compostos de pept\u00eddeos metab\u00f3licos relacionados incluindo <a href=\"https:\/\/medsbase.com\/pt-pt\/semaglutide\/\">Semaglutide<\/a> (parceiro CagriSema), <a href=\"https:\/\/medsbase.com\/pt-pt\/tirzepatide\/\">Tirzepatide<\/a> (comparador duplo GLP-1\/GIP), e <a href=\"https:\/\/medsbase.com\/pt-pt\/retatrutide\/\">Retatrutide<\/a> (comparador triplo-agonista). Guia comparativo: <a href=\"https:\/\/medsbase.com\/pt-pt\/retatrutide-vs-tirzepatide\/\">Retatrutida vs Tirzepatida \u2014 agonista triplo vs agonista duplo<\/a>.<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 An\u00e1logo de amilina de a\u00e7\u00e3o prolongada (Novo Nordisk AM833)<br \/>\n\u2705 Agonista de recetores de amilina\/calcitonina<br \/>\n\u2705 Parceiro de combina\u00e7\u00e3o CagriSema com semaglutida<br \/>\n\u2705 Saciedade do tronco cerebral + supress\u00e3o de glucagon<br \/>\n\u2705 Dosagem semanal (~159 horas de meia-vida)<\/p>\n<p><strong>Cagrilintide<\/strong> cont\u00e9m composto de p\u00e9ptido sint\u00e9tico.<\/p>","protected":false},"featured_media":70938,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6284,5441],"class_list":["post-70747","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-cagrilintide","product_tag-peptide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product\/70747","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/comments?post=70747"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/media\/70938"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/media?parent=70747"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product_brand?post=70747"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product_cat?post=70747"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product_tag?post=70747"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}